New Study Finds Low Risk of Second Cancers After Early Breast Cancer Treatment
A comprehensive study shows that women treated for early breast cancer face a low long-term risk of developing second primary cancers, with most risks being manageable and outweighed by treatment benefits.
Recent research published in The BMJ provides reassuring evidence regarding the long-term health outcomes of women treated for early breast cancer. The study analyzed data from nearly half a million women in England diagnosed between 1993 and 2016, tracking the incidence of second primary cancers over a follow-up period of up to two decades. It found that the overall increase in the risk of developing a second cancer was modest, approximately 2–3% above the risk levels of the general population.
Specifically, about 13.6% of women developed a non-breast second cancer—most commonly affecting the womb, lungs, or bowel—representing a 2.1% excess compared to expectations. Additionally, 5.6% experienced a contralateral breast cancer, which is a new cancer on the opposite breast, with a 3.1% higher risk than in women without prior breast cancer.
The study revealed that age at initial diagnosis influenced the risk levels: younger women faced a higher relative risk of contralateral breast cancer, whereas the risk of non-breast second cancers was relatively consistent across age groups. Treatment type also played a role; radiotherapy was associated with increased rates of lung and contralateral breast cancers, while endocrine therapy was linked to uterine cancers, and chemotherapy correlated with a risk of acute leukemia. The researchers estimate that approximately 7% of the excess second cancers could be attributed to adjuvant therapies, but emphasize that these treatments' benefits in reducing recurrence generally outweigh the small risks.
While acknowledging some limitations due to incomplete data on family history, genetic predispositions, and lifestyle factors, the study offers valuable insights. It suggests that most women with early invasive breast cancer can be reassured about their relatively low long-term risk of developing additional cancers. The findings underline the importance of personalized treatment planning and provide useful information for clinicians and patients making informed decisions about breast cancer management.
Ultimately, these results highlight that the benefits of contemporary breast cancer treatments significantly surpass the minimal risk of secondary cancers, and that patients should have access to detailed risk information to better plan their futures.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative High-Throughput Antibody Testing Platform to Accelerate Disease Research and Therapeutic Development
A new high-throughput antibody testing platform developed by University of Illinois researchers can rapidly generate and analyze large antibody libraries, accelerating disease research, vaccine development, and therapy discovery.
Large-Scale Study Finds No Advantage in Auditory Processing Among Musicians
A large-scale study reveals that musical training does not enhance early neural processing of sounds, challenging previous beliefs and emphasizing the importance of rigorous scientific research.
Insurers Challenge State Laws Limiting Surprise Ambulance Bills
Many families face unexpected and costly ambulance bills, prompting states to pass laws protecting consumers, though insurers often oppose these efforts. This article explores the ongoing battle over surprise ambulance billing and the need for nationwide regulation.
Recall of Chicken Alfredo Meals Due to Listeria Contamination Causing Three Deaths
Major grocery chains have recalled certain chicken Alfredo meals following a listeria outbreak that caused three deaths and multiple illnesses across the United States. Consumers should check their products and discard affected items to prevent serious health risks.